EPCAM and neoplasm: Additionally, EpCAM has been demonstrated to inhibit tumor-infiltrating immune cells through an interaction with its extracellular ligand, leukocyte-associated immunoglobulin-like receptor (LAIR1) [98], thus explaining the underlying mechanism of active immune escape mechanisms in EpCAM-expressing tumors.